Thomas Regnier
Kyoto Pharmaceutical University
5 Papers
68 Citations
Thomas Regnier is an academic researcher from Kyoto Pharmaceutical University. The author has contributed to research in topics: Total synthesis & Michael reaction. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CLpro inhibitors
Thomas Regnier,Diganta Sarma,Koushi Hidaka,Usman Bacha,Ernesto Freire,Yoshio Hayashi,Yoshio Hayashi,Yoshiaki Kiso +7 more
TL;DR: A series of trifluoromethyl, benzothiazolyl or thiazolyL ketone-containing peptidic compounds as SARS-CoV 3CL protease inhibitors were developed and their potency was evaluated by in vitro protease inhibitory assays.
55
Total synthesis of (+)-negamycin and its 5-epi-derivative
Shigenobu Nishiguchi,Magne O. Sydnes,Akihiro Taguchi,Thomas Regnier,Tetsuya Kajimoto,Manabu Node,Yuri Yamazaki,Fumika Yakushiji,Yoshiaki Kiso,Yoshio Hayashi,Yoshio Hayashi +10 more
TL;DR: In this paper, a chiral amine (−)-21 [(1S,2R)-(−)-2-methoxybornyl-10-benzylamine] was added to the α,β-unsaturated carbonyl moiety of key intermediate 8, thus establishing the second chiral center in (+)-negamycin.
22
Efficient total synthesis of (+)-negamycin, a potential chemotherapeutic agent for genetic diseases.
Yoshio Hayashi,Yoshio Hayashi,Thomas Regnier,Shigenobu Nishiguchi,Magne O. Sydnes,Daisuke Hashimoto,Junya Hasegawa,Takahiro Katoh,Tetsuya Kajimoto,Masataka Shiozuka,Ryoichi Matsuda,Manabu Node,Yoshiaki Kiso +12 more
TL;DR: An efficient strategy for the total synthesis of (+)-negamycin using commercially available achiral N-Boc-2-aminoacetaldehyde as starting material with 42% overall yield for a limited number of steps is described.
22